Browsing Tag

hyperphosphatemia

XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric…

Jason Junior Nov 16, 2023

WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet…

Health

Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China

Jason Junior Jul 13, 2023

WALTHAM, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet…

Health

Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum…

Jason Junior Nov 10, 2022

Topline Data Expected by Year End 2022 On Track to File the NDA in 2023 LOS ALTOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for…

Health

Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s…

Jason Junior Oct 26, 2022

Multiple Data Presentations Support the Company’s Pipeline of Innovative Product Candidates aimed at Improving the Quality-of-Life for Patients Battling Kidney Disease Independently Hosted Key Opinion Leader Panel to Highlight Potential…

Health

Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s…

Jason Junior Aug 24, 2022

LOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the acceptance of two…

Health

Unicycive Reports Key Findings from Market Research with Nephrologists

Jason Junior Jul 20, 2022

Renazorb product profile rated as best-in-class phosphate binder Nephrologists report high prescribing intent for Renazorb pending FDA approval LOS ALTOS, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. …

Health

Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia

Jason Junior Jun 2, 2022

LOS ALTOS, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease today announced the initiation of its pivotal…

Health

The Hyperphosphatemia Treatment Market Is Expected To Reach $5.5 Billion By 2026 Due To Increasing…

Jason Junior May 20, 2022

LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- According to The Business Research Company’s research report on the hyperphosphatemia treatment market, increasing chronic diseases among patients is driving the growth of the hyperphosphatemia…

Health

How Does Phosphate Binder Type Affect the Heart in Hemodialysis?

Jason Junior May 19, 2021

Non-calcium-based phosphate binders weren't any better at reducing cardiovascular events than calcium-based binders in dialysis patients, the…